- ￥416 - 4200
- MedChemExpress(MCE)
- 美国
- HY-19569
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
ABT-494
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1310726-60-3
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥795.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥416.0 |
| 规格： | 5 mg | 产品价格： | ￥950.0 |
| 规格： | 10 mg | 产品价格： | ￥1400.0 |
| 规格： | 25 mg | 产品价格： | ￥2900.0 |
| 规格： | 50 mg | 产品价格： | ￥4200.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Upadacitinib
CAS No. : 1310726-60-3
MCE 国际站：Upadacitinib
产品活性：Upadacitinib (ABT-494) 是一种高效的、具有口服活性的、选择性 Janus 激酶 1 (JAK1) 抑制剂 (IC50=43 nM)。Upadacitinib 对 JAK1 的选择性约为 JAK2 (200 nM）的 74 倍。Upadacitinib 可用于多种自身免疫性疾病的研究。
研究领域：Epigenetics | Protein Tyrosine Kinase/RTK | JAK/STAT Signaling | Stem Cell/Wnt
作用靶点：JAK
In Vitro: In biochemical assays, Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance). The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit–risk profile in patients with RA range.
In Vivo: Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) demonstrates efficacy in rat arthritis models.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Epigenetics Compound Library | Immunology/Inflammation Compound Library | JAK/STAT Compound Library | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Stem Cell Signaling Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | Anti-Prostate Cancer Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Off-patent Drug Library | Autoimmune Disease Compound Library | Highly Selective Inhibitors Library | Ruxolitinib | Tofacitinib | Deucravacitinib | Baricitinib | AG490 | Fedratinib | Pacritinib | Ritlecitinib | Momelotinib | WP1066 | Filgotinib | Butyzamide | RO8191 | AZD-1480 | AT9283 | Peficitinib | Abrocitinib | Itacitinib | Cucurbitacin I | CHZ868 | (E/Z)-Zotiraciclib | Pyridone 6 | Gandotinib | JAK2 JH2 Tracer | Atractylenolide I | Delgocitinib
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
